

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 46275

Title: Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance?

Reviewer's code: 03723215

Reviewer's country: South Korea

Science editor: Ruo-Yu Ma

Reviewer accepted review: 2019-02-26 17:47

Reviewer performed review: 2019-02-27 18:54

Review time: 1 Day and 1 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Thanks to authors for submitting concise and well-structured review.

INITIAL REVIEW OF THE MANUSCRIPT



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 46275

Title: Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance?

Reviewer's code: 02535507

Reviewer's country: Italy

Science editor: Ruo-Yu Ma

Reviewer accepted review: 2019-03-03 10:29

Reviewer performed review: 2019-03-04 10:48

Review time: 1 Day

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

In this review article Suzuki et al discussed about the problem of antibiotic resistance in the setting of H. pylori eradication. They suggest that an optimal therapy should be effective and, at the same time, it should not be able to select resistant strains. In this

regard they propose that dual therapy with vonoprazan could be the solution. The main problem of this article is that vonoprazan is currently available only on Japanese market. This point must be underlined and discussed. Indeed, it is questionable whether vonoprazan is a lesson from Japan to apply worldwide or a limited geographic phenomenon. Page 6: please delete furazolidone from the list, since it is not recommended by any guideline and it may have harmful potential and not approved for use in humans in many countries. Dual therapy cannot be used in subjects with penicillin allergy. In this case, a tailored therapy could be an alternative. Indeed, the possibility of first-line personalization of antibiotic treatment based on a non invasive assessment of susceptibility should be discussed more in depth (see Ierardi E et al, World J Gastroenterol 2017). A table summarizing all the studies with vonoprazan-based dual therapy may make the paper more appealing for the readers. Additionally, specific meta-analyses must be cited, if available. A minor linguistic revision is necessary due to some typos.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☒ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<https://www.wjgnet.com>

[Y] No